The aims of the investigators' study are to investigate the effect of H.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.
Accumulating evidence shows that Helicobacter pylori protects against some metabolic and immunological diseases in which the development of these diseases coincide with temporal or permanent dysbiosis. Helicobacter pylori eradication therapy has the potential to improve symptoms of functional dyspepsia. The aims of our study are to investigate the effect of H.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
Change of gut microbiome
Change of gut microbiome at 3 months, and 6 months regardless of Helicobater positive or negative
Time frame: at 3 months, and 6 months
Symptom of dyspepsia
Improvement of NDI-K, HADS,SEQ-FD at 3 and 6 months
Time frame: at 3 months, and 6 months
Eradication of helicobacter pylori
Eradication rate of helicobacter pylori at 3 months
Time frame: at 3 months
Histologic finding of UGI tract
Change of accumulationof inflammatory cells, eosinophils of esophagus, stomachm duodenal mucosal biopsy
Time frame: at initial and 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.